/manager/Index ${session.getAttribute("locale")} 5 Prognostic factors of all-cause mortalities in continuous ambulatory peritoneal dialysis: a cohort study /manager/Repository/uon:19471  2.19 adds no further benefit. Serum albumin, hemoglobin, SBP, and UF volume are also associated with mortality. However, our study may face with selection and other unobserved confounders, so further randomized controlled trials are required to confirm these cutoffs.]]> Wed 11 Apr 2018 14:03:21 AEST ]]> Progression of chronic kidney disease: an illness-death model approach /manager/Repository/uon:30809 Wed 02 Oct 2019 10:27:56 AEST ]]> Periodontitis as the risk factor of chronic kidney disease: mediation analysis /manager/Repository/uon:36550 Tue 30 Jun 2020 13:13:55 AEST ]]> Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis /manager/Repository/uon:11389 Sat 24 Mar 2018 08:10:00 AEDT ]]> Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data /manager/Repository/uon:4618 Sat 24 Mar 2018 07:21:53 AEDT ]]> Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients /manager/Repository/uon:31991 1 year (RAAS2). An augmented inverse-probability weighting (AIPW) method was used to estimate potential-outcome mean (POM) and average treatment-effect (ATE). Multi-logit and Poisson regressions were used for treatment and outcome models, respectively. Analyses were stratified by ESRD, death before/after ESRD for diabetic and non-diabetic groups. STATA 14.0 was used for statistical analyses. Results: Among 15,032 diabetic patients, 2346 (15.6%), 2351 (18.5%), and 1607 (68.5%) developed ESRD, died before ESRD, and died after ESRD, respectively. Only RAAS2 effect was significant on ESRD, death before and after ESRD. The ESRD rates were 12.9%, versus 20.0% for RAAS2 and non-RAAS, respectively, resulted in significant risk differences (RD) of -7.2% (95% CI: -8.8%, -5.5%), and a numbers needed-to-treat (NNT) of 14. Death rates before ESRD for these corresponding groups were 14.4% (12.9%, 15.9%) and 19.6% (18.7%, 20.4%) with a NNT of 19. Death rates after ESRD in RAAS2 was lower than non-RASS group (i.e., 62.8% (55.5%, 68.9%) versus 68.1% (65.9%, 70.4%)) but this was not significant. RAAS2 effects on ESRD and death before ESRD were persistently significant in non-diabetic patients (n = 17,074) but not for death after ESRD with the NNT of about 15 and 16 respectively. Conclusions: Receiving RAAS blockade for 1 year or longer could prevent both CKD progression to ESRD and premature mortality.]]> Mon 23 Sep 2019 13:22:31 AEST ]]>